Enzyme inhibitors and enzyme substrates

Pravastatin sodium is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.An HMGCR inhibitor which blocks cholesterol synthesis.

Pravastatin sodium is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.An HMGCR inhibitor which blocks cholesterol synthesis.

Pronase is a mixture of several nonspecific endo- and exoproteases that digest proteins down to single amino acids.Application:Use Pronase to completely hydrolyze proteins in research applications. Pronase is used for the degradation of proteins

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM, respectively.

RG-13022 is a Tyrosine kinase tyrphostin. Reports indicate that RG-13022 suppresses epidermal growth factor (EGF)-stimulated cancer cell proliferation in cancer cell studies. Additionally, RG-13022 has been described to inhibit EGF, platelet-dervied

RG-13022 is a Tyrosine kinase tyrphostin. Reports indicate that RG-13022 suppresses epidermal growth factor (EGF)-stimulated cancer cell proliferation in cancer cell studies. Additionally, RG-13022 has been described to inhibit EGF, platelet-dervied

RG-13022 is a Tyrosine kinase tyrphostin. Reports indicate that RG-13022 suppresses epidermal growth factor (EGF)-stimulated cancer cell proliferation in cancer cell studies. Additionally, RG-13022 has been described to inhibit EGF, platelet-dervied

RG-13022 is a Tyrosine kinase tyrphostin. Reports indicate that RG-13022 suppresses epidermal growth factor (EGF)-stimulated cancer cell proliferation in cancer cell studies. Additionally, RG-13022 has been described to inhibit EGF, platelet-dervied